GH Research
CJC-1295 with DAC
Buy CJC-1295 with DAC in Australia — >99.2% HPLC tested with batch-specific COA. Same-day Australian dispatch.
GHRH analogue research compound with Drug Affinity Complex (DAC) modification. 30-amino acid peptide with four substitutions of GHRH(1-29) plus a maleimidopropionic acid linker for covalent albumin binding and extended half-life. Investigated in pituitary somatotroph signalling and GHRH receptor binding literature.
Institutional pricing
Volume pricing applies automatically at checkout when commerce is live. For bulk institutional orders or custom quantities, contact pillarresearch@pm.me.
CJC-1295 with DAC
Estimated launch price: $99 AUD
Add to cart is unavailable until launch. Enter your email and we'll notify you the moment CJC-1295 with DAC is in stock.
No spam. Unsubscribe anytime. For research use only.
Researchers studying CJC-1295 with DAC frequently study
CJC-1295 with DAC Overview
CJC-1295 with DAC is a 30-amino-acid synthetic analogue of GHRH(1-29) modified with four amino-acid substitutions (D-Ala, Gln, Ala, Leu) and a maleimidopropionic acid (MPA) Drug Affinity Complex (DAC) linker. The DAC linker enables covalent binding to circulating albumin, dramatically extending the active half-life from minutes to days and supporting weekly dosing in published research.
History
Developed in the early 2000s as part of research into long-acting GHRH analogues, CJC-1295 with DAC was investigated for its ability to sustain pulsatile GH release patterns through albumin binding. The compound established the DAC platform as a strategy for half-life extension of peptide research compounds.
CJC-1295 with DAC Structure
Research Findings
CJC-1295 with DAC has been studied in pituitary somatotroph research, GHRH receptor binding, and pulsatile GH secretion modelling. The DAC linker mechanism has been characterised as a generalisable half-life extension strategy for peptide research compounds.
Key Areas of Research:
- •Somatotroph signalling: GHRH receptor binding and downstream cAMP signalling
- •GH pulse dynamics: Pulsatile secretion modelling under sustained stimulation
- •Half-life engineering: DAC albumin-binding mechanism characterisation
References
References are provided for research context. Pillar Research does not endorse or interpret published findings as therapeutic claims.
CJC-1295 with DAC — research questions
Common questions for Australian researchers about CJC-1295 with DAC.
What is CJC-1295 with DAC?
CJC-1295 with DAC is a 30-amino-acid synthetic GHRH analogue modified with a Drug Affinity Complex (DAC) linker that covalently binds circulating albumin to extend half-life. It is supplied for in vitro laboratory research under the RUO framework.
What is the difference between CJC-1295 with and without DAC?
The DAC version conjugates a maleimidopropionic acid (MPA) linker to enable covalent albumin binding, extending the half-life from hours to days. The non-DAC form has a shorter half-life. The DAC form is the long-acting research compound.
What receptor does CJC-1295 target?
The GHRH receptor (GHRH-R), expressed primarily on pituitary somatotrophs. Activation triggers Gαs–cAMP signalling and growth hormone release in physiological systems.
Is CJC-1295 legal in Australia?
CJC-1295 is classified as Schedule 4 (prescription-only) under the Australian Poisons Standard. It can be lawfully supplied for in vitro research purposes under the Research Use Only (RUO) framework. It is not listed on the Australian Register of Therapeutic Goods (ARTG) and is not a therapeutic good under the Therapeutic Goods Act 1989 (Cth).
How is CJC-1295 verified by Pillar Research?
Every batch is independently HPLC and mass spectrometry verified by a third-party Australian laboratory. The batch-specific Certificate of Analysis is downloadable from this page.
How should CJC-1295 be stored?
Store lyophilised vials at 2–8 °C, protected from light and moisture, in the original sealed vial. After reconstitution, store at 2–8 °C for short-term use or −20 °C for longer storage. Avoid repeated freeze–thaw cycles.